Thousands of Australians with multiple sclerosis could lose subsidised access to ocrelizumab and ofatumumab as a PBS pricing dispute heads to the PBAC.
Thousands of Australians with multiple sclerosis could lose subsidised access to ocrelizumab and ofatumumab as a PBS pricing dispute heads to the PBAC.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.